Notice of Extraordinary General Meeting in DiaGenic ASA
Reference is made to the CEO announcement on June 26th 2012.
The Board of directors of DiaGenic ASA (the “Company”) hereby summons for an extraordinary general meeting.
Time: 14 August 2012 at 13:00 hours (CET)
Place: Grenseveien 92, Oslo, Norway
Agenda:
- Opening of the meeting by the acting chairman of the Board Ingrid Wiik, including registration of shareholders present
- Election of chairman of the meeting and a person to co-sign the minutes
- Approval of notice and agenda of the general meeting
- Approval of a new option program in connection with the appointment of new Chief Executive Officer
Please see attached Notice for Extraordinary General Meeting for more details on the agenda.
Information regarding the extraordinary general meeting, including this notice with attachments is available at the Company's website www.diagenic.com
Oslo, 26 June 2012
On behalf of the Board of directors of DiaGenic ASA
Ingrid Wiik
Acting chairman of the Board
Telephone: +47 900 51 433
E-mail: ingrid@iwiik.com
About DiaGenic ASA
DiaGenic seeks to create value for patients, partners, and investors by developing innovative and more patient friendly methods for early detection of diseases utilizing DiaGenic’s unique concept. The concept implies that a disease evokes systemic responses in the blood unique for the disease, and which can be measured by using blood samples.
DiaGenic is a world leader in identifying these gene expression signatures in peripheral blood and is focused on the development of biomarkers in the field of Alzheimer’s disease and Parkinson’s disease. DiaGenic’s Alzheimer’s disease development program includes the CE marked diagnostic test ADtect®, for detection of mild to moderate Alzheimer’s disease, and MCItect®which is under development for identifying patients with very early stages of Alzheimer’s disease (prodromal AD).
DiaGenic’s concept is protected through an extensive patent portfolio. DiaGenic promotes its products and services towards leading pharmaceutical, imaging and diagnostic companies. DiaGenic is located in Norway and listed on the Oslo Stock Exchange. For more information please visit: www.diagenic.com